$AMGN Recent News Amgen ends trials of stomach-cancer

New Post Public Reply Private Reply Replies (0) Message Board

Dec 14, 2014 at 10:35 AM

$AMGN Recent News

Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt

Dividend Challengers: 24 Increases Expected By February 28 3:17 p.m. Dec. 13, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
How Can Drugmakers Handle New Pricing Pressures? 4:38 p.m. Dec. 11, 2014 - Investors Business Daily
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Gilead Sciences Bucks Trend In Biotech Short Interest 11:06 a.m. Dec. 11, 2014 - benzinga.com
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog 3:10 p.m. Dec. 10, 2014 - Zacks.com
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) - Analyst Blog 12:54 p.m. Dec. 10, 2014 - Zacks.com
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Bristol-Myers sets up collaborative cancer study in Japan 7:36 a.m. Dec. 10, 2014 - Seeking Alpha
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog 6:20 p.m. Dec. 9, 2014 - Zacks.com
Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog 5:20 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Amgen Successfully Expands Xgeva Label in the U.S. - Analyst Blog 5:00 p.m. Dec. 9, 2014 - Zacks.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog 3:15 p.m. Dec. 9, 2014 - Zacks.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Amgen and Merck team up in melanoma 5:04 p.m. Dec. 8, 2014 - Seeking Alpha
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA For Advanced Melanoma 3:21 p.m. Dec. 8, 2014 - benzinga.com

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Era for Small Cell Lung Cancer: Breakthroughs & Challenges

Unpacking Small Cell Lung Cancer Progress These days, it feels like we're standing on the brink of something real big in the fight against small cell lung cancer. And I'm not talking about pie-in-the-sky ideas—there are some serious game changers coming down the pike, folks. You see, in the past, this aggressive cancer type was pretty much a death sentence. But thanks...

Beta Bionics Lawsuit: What Investors Need to Know

Beta Bionics Takes a Hit: What's Behind the Drop? You ever have one of those moments where you wonder if you missed a memo? Well, folks investing in Beta Bionics (NASDAQ:BBNX) sure might feel that way after a staggering 37% plunge in their stock. The issue here isn't just the drop—it's what spurred it: a securities class action lawsuit alleging some murky disclosures...

Gildan Faces Investor Class Action After Stock Tumbles

Shake-Up at Gildan: Investors Take Legal Action Gildan Activewear Inc. (NYSE:GIL) got themselves in hot water, folks. They've landed on the wrong side of an investor class action lawsuit after claims of shady business tactics sent their stock plummeting like a rock in June. We're talking about an 18.75% nosedive here. That's not just a slip—it's a fall worth wearing a...

US State Dept. & IICA: Strengthening Disaster Response

Bridging Borders to Tackle Disasters It seems like everyone and their grandma talks disaster aid, but when two giants like the US State Department's Bureau of Disaster and Humanitarian Response (DHR) and the Inter-American Institute for Cooperation on Agriculture (IICA) grab a coffee—real serious action is brewing. Why This Matters The partnership's not just talk. Let's...

Ferrovial's 2026 Growth: North America Drives Success

Solid Gains Across the Board Right off the bat, Ferrovial's 2026 report card screams 'win'. For the first three quarters, they clocked in a hefty 21.8% boost in adjusted EBITDA, and revenue didn't dawdle either, climbing 10.8%—not exactly a stroll in the park to accomplish. North America's No Joke Ferrovial's got a clear hero in their narrative and it's North America....

Webull Faces Class Action: Deadline Looms Dec 2026

Sinking Shares: The Webull Saga Unfolds Shady business practices can really make a stock take a nosedive, and that's what's happening with Webull Corporation, trading under NASDAQ:BULL. The alarm bells started ringing when the truth about their operations and ties to China came out. Turns out, what looked like a stable American fintech platform had its roots digging deep...

Coulomb Solutions Powers Ahead with ReadyGrid Launch

Breaking New Ground with ReadyGrid If you've been keeping an eye on the energy storage landscape, today's a big day. Coulomb Solutions, Inc. (CSI) is shaking things up by spinning off ReadyGrid, its own dedicated mobile energy storage powerhouse. The move is designed to tackle the pressing power challenges that have been nagging industries across the board, from...

CTCA Tackles Trust Issues in $B-illion Card Market

Gaps in a Booming Industry Trading cards might sound like kid stuff, but don’t be fooled—there's billions riding on paper and ink these days. Yet, a dark cloud hovers over the trading card scene, where questions of transparency and accountability loom large. Digital repacks and those dicey randomized packs have folks questioning what’s in the mix: Is it a safe bet...

Tempo's Protein Max Meals: A High-Protein Revolution

Packed Protein, Zero Hassle Every once in a while, something comes along in the food sector that changes the game. Tempo's Protein Max meals might just be it. Launching with a hefty 40 grams of protein in every serving, these meals promise a powerful punch for anyone who's serious about meeting their protein counts without spending hours in the kitchen. Two minutes flat...

Doximity Lawsuit: What Investors Need to Know Now

Lawsuit Clouds Hang Over Doximity The courtroom isn't typically where you find stocks making headlines, but Doximity's recent plunge isn't just a market hiccup. After a rough patch, an alleged misstep lands them squarely under the legal microscope, and investors have questions. Tracing Doximity's Rocky Financial Reports First, let's rewind to November last year. Doximity...